Oncopeptides AB (LTS:0RN4) Ending Cash Position : kr178.54 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Ending Cash Position?

Oncopeptides AB's Ending Cash Position for the quarter that ended in Dec. 2024 was kr178.54 Mil.

Oncopeptides AB's quarterly Ending Cash Position declined from Jun. 2024 (kr383.28 Mil) to Sep. 2024 (kr250.01 Mil) and declined from Sep. 2024 (kr250.01 Mil) to Dec. 2024 (kr178.54 Mil).

Oncopeptides AB's annual Ending Cash Position declined from Dec. 2022 (kr344.52 Mil) to Dec. 2023 (kr173.41 Mil) but then increased from Dec. 2023 (kr173.41 Mil) to Dec. 2024 (kr178.54 Mil).

Oncopeptides AB Ending Cash Position Historical Data

The historical data trend for Oncopeptides AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Ending Cash Position Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

840.26

362.19

344.52

173.41

178.54

Oncopeptides AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															173.41	104.83	383.28	250.01	178.54

Oncopeptides AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Oncopeptides AB's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	173.407	+	5.129
	=	178.54

Oncopeptides AB's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	250.509	+	-71.973
	=	178.54

Oncopeptides AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines

No Headlines